COVID-19 Impact Analysis:

Pharmaceutical and biotech companies together with governments globally are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges.

Currently, about 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn, is expected to have a significant impact on the global Factor V Leiden thrombophilia treatment market.

Top Impacting Factors:

• The increase in geriatric population and the rise in cases of injury, obesity, smoking, surgery, and pregnancy are the primary factors driving market expansion.
• The rise in the global healthcare expenditure, a surge in diabetic population, the increase in cancer patients, and the increase in the prevalence of cardiovascular disease are factors driving the market growth.
• The increase in the number of mutations in the F5 gene is expected to drive the Factor V Leiden thrombophilia treatment market during the forecast years.
• Additionally, the increase in use of oral contraceptives, hormone replacement treatment, and the growth in occurrences of the antiphospholipid syndrome are also expected to boost the market over the forecast period.
• Furthermore, the introduction of new medications, the increase in R&D activities, and the increase in investment by major companies for Factor V Leiden thrombophilia treatment are boosting the market globally. 
• However, the lack of awareness in patients regarding Factor V Leiden thrombophilia and lack of skilled health workforce are hampering the growth of the Factor V Leiden thrombophilia market. 

Market Trends:

New Product Launches to Flourish Factor V Leiden Thrombophilia Market

In October 2019, Johnson & Johnson’s Xarelto was approved by the FDA to help prevent blood clots in acutely ill patients without a high risk of bleeding during and after hospitalization. 

In December 2020, Glenmark Pharmaceuticals received a tentative approval by the United States Food and Drug Administration (USFDA) for Dabigatran Etexilate capsules in the strengths of 75 mg, 110 mg, and 150 mg. The approved product is a generic version of Boehringer Ingelheim Pharmaceuticals' Pradaxa capsules.
 

Key Benefits of Report:

• This study presents the analytical depiction of the Factor V Leiden thrombophilia treatment along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Factor V Leiden thrombophilia treatment market share.
• The current market is quantitatively analyzed from 2020 to 2030 to highlight the Factor V Leiden thrombophilia treatment market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed Factor V Leiden thrombophilia treatment market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions Answered in Factor V Leiden Thrombophilia Treatment Market Report:

• Who are the leading market players active in Factor V Leiden thrombophilia treatment market?
• What current trends will influence the Factor V Leiden thrombophilia treatment market in the next few years?
• What are the driving factors, restraints, and opportunities in the Factor V Leiden thrombophilia treatment market?
• What future projections would help in taking further strategic steps?
• What is Factor V Leiden thrombophilia treatment?
• What is Factor V Leiden thrombophilia treatment market prediction in the future?
• Who are the leading global players in the Factor V Leiden thrombophilia treatment market?
• What are the current trends and predicted trends?
• What are the key benefits of the Factor V Leiden thrombophilia treatment market report?